---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-046804"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2023-10-04T23:59:59+00:00"
generated_at: "2026-06-10T04:36:04.976569+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q1 FY2024 revenue $78.7M, pro-forma +5.7%; adj. loss $(0.12)/share

## Summary
- Net sales $78.7M (ex-Dialysis/BioSentry +5.7% YoY); Med Tech +13.3% on Auryon +25.7%, NanoKnife +34.5%.
- GAAP net income $45.9M ($1.15 EPS) includes $47.8M gain from Dialysis/BioSentry sale; adjusted loss $(0.12)/share.
- Completed sale of Dialysis & BioSentry to Merit Medical for $100M cash; proceeds used to extinguish debt.
- Reaffirmed FY2024 outlook: net sales $328-333M, gross margin ~50-52%, adjusted EPS loss $(0.28)-(0.34).
- Cash & equivalents $57.6M at Aug 31, 2023, up from $44.6M at May 31, 2023; debt-free post-divestiture.

## SEC filing metadata
- accession: 0001140361-23-046804
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2023-10-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036123046804/0001140361-23-046804-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036123046804/ef20011918_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-046804
- JSON: https://secwatch.observer/filing/0001140361-23-046804.json
- Plain text: https://secwatch.observer/filing/0001140361-23-046804.txt

## Key facts
- Earnings Releases
  ANGIODYNAMICS INC reported the first quarter of fiscal year 2024, which ended August 31, 2023 results: revenue $78.7 million, net income $45.9 million, EPS $1.15. Guidance reaffirmed.
  - Period: the first quarter of fiscal year 2024, which ended August 31, 2023
  - Revenue: $78.7 million
  - Net income: $45.9 million
  - EPS: $1.15
  - Guidance: reaffirmed
  - Result: reported results
  source text: 795-1408 AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance Fiscal Year 2024 First Quarter Highlights • Net sales of $78.7 million as reported o Includes $0.7 million of Dialysis and BioSentry Biopsy Tract Sealant System sales o Net sales increased 5.7% on a pro-forma basis when excluding Dialysis and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1275187/000114036123046804/0001140361-23-046804-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.